Response to omalizumab in allergic asthma patients from different racial backgrounds
نویسندگان
چکیده
منابع مشابه
Predicting and evaluating response to omalizumab in patients with severe allergic asthma.
BACKGROUND Omalizumab is a monoclonal antibody indicated for treatment of severe persistent allergic asthma inadequately controlled despite optimal controller therapy. We investigated whether patient selection could be targeted further. METHODS Data from seven randomized controlled omalizumab trials were analyzed to investigate whether pre-treatment patient baseline clinical characteristics c...
متن کاملPredicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.
STUDY OBJECTIVE To determine baseline characteristics predictive of response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. DESIGN Pooled analysis of two multicenter, double-blind, randomized, placebo-controlled phase III studies with omalizumab. PATIENTS One thousand seventy allergic asthma patients symptomatic despite moderate-to-high doses (mean, 725 micro g/d) of...
متن کامل270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
269 Refractory Chronic Urticaria Treated with Omalizumab Martinez Saenz, NP, Ramírez Del Pozo, ME, Lopez Tiro JJ, and Javier Gomez Vera, MD. Alergia e inmunologia clínica, Hospital Regional Lic. Adolfo Lopez Mateos, Distrito Federal, Mexico. Background: Chronic urticaria (CU) is a common disorder characterized by recurrent episodes of urticaria pruritic erythematous lesions, associated with ang...
متن کاملOmalizumab decreases IgE production in patients with severe allergic asthma
printing supported by . Visit Chiesi at Stand B2.10 MONDAY, SEPTEMBER 3RD 2012 cates that age and sex are the major risk factors. Detailed physiological mechanisms of the changing sex ratio are not fully known. We investigated the influence of gender in anti-IgE treated asthmatics. Methods: We pooled data from ten published studies from 1999 with more of our data of severe persistent asthmatics...
متن کامل4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
BACKGROUND Omalizumab is licensed as add-on therapy for patients with severe allergic asthma. Response is in most studies scored by the physician's global evaluation of treatment effectiveness (GETE). A good clinical and validated parameter for treatment response is currently missing. Also, there are no established criteria for identifying patients who will respond to omalizumab based on pre-tr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Allergy and Clinical Immunology
سال: 2020
ISSN: 0091-6749
DOI: 10.1016/j.jaci.2019.12.793